ANAB has 36-month beta value of -0.24. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ANAB is 24.22M, and currently, short sellers hold a 19.07% ratio of that float. The average trading volume of ANAB on July 04, 2024 was 354.18K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ANAB) stock’s latest price update
The stock of AnaptysBio Inc (NASDAQ: ANAB) has increased by 4.01 when compared to last closing price of 23.94. Despite this, the company has experienced a 2.81% gain in its stock price over the last five trading sessions. zacks.com reported 2024-05-09 that AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.64 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to loss of $1.58 per share a year ago.
ANAB’s Market Performance
AnaptysBio Inc (ANAB) has seen a 2.81% rise in stock performance for the week, with a 6.09% gain in the past month and a 20.17% surge in the past quarter. The volatility ratio for the week is 4.09%, and the volatility levels for the past 30 days are at 4.24% for ANAB. The simple moving average for the past 20 days is 3.95% for ANAB’s stock, with a 17.29% simple moving average for the past 200 days.
Analysts’ Opinion of ANAB
Many brokerage firms have already submitted their reports for ANAB stocks, with Leerink Partners repeating the rating for ANAB by listing it as a “Outperform.” The predicted price for ANAB in the upcoming period, according to Leerink Partners is $47 based on the research report published on April 16, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see ANAB reach a price target of $56. The rating they have provided for ANAB stocks is “Overweight” according to the report published on April 11th, 2024.
Wedbush gave a rating of “Outperform” to ANAB, setting the target price at $34 in the report published on March 12th of the current year.
ANAB Trading at 4.22% from the 50-Day Moving Average
After a stumble in the market that brought ANAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.45% of loss for the given period.
Volatility was left at 4.24%, however, over the last 30 days, the volatility rate increased by 4.09%, as shares surge +4.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +26.65% upper at present.
During the last 5 trading sessions, ANAB rose by +2.81%, which changed the moving average for the period of 200-days by +27.69% in comparison to the 20-day moving average, which settled at $24.01. In addition, AnaptysBio Inc saw 16.25% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ANAB starting from FENTON DENNIS M, who sale 1,950 shares at the price of $23.17 back on Jun 21 ’24. After this action, FENTON DENNIS M now owns 1,950 shares of AnaptysBio Inc, valued at $45,182 using the latest closing price.
RENTON HOLLINGS, the Director of AnaptysBio Inc, sale 1,950 shares at $23.16 during a trade that took place back on Jun 18 ’24, which means that RENTON HOLLINGS is holding 1,950 shares at $45,162 based on the most recent closing price.
Stock Fundamentals for ANAB
Current profitability levels for the company are sitting at:
- -7.06 for the present operating margin
- 0.9 for the gross margin
The net margin for AnaptysBio Inc stands at -7.11. The total capital return value is set at -0.43. Equity return is now at value -136.73, with -34.11 for asset returns.
Based on AnaptysBio Inc (ANAB), the company’s capital structure generated 0.87 points at debt to capital in total, while cash flow to debt ratio is standing at -0.45. The debt to equity ratio resting at 6.53. The interest coverage ratio of the stock is -8.08.
Currently, EBITDA for the company is -135.82 million with net debt to EBITDA at -1.88. When we switch over and look at the enterprise to sales, we see a ratio of 41.55. The receivables turnover for the company is 3.24for trailing twelve months and the total asset turnover is 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.53.
Conclusion
To put it simply, AnaptysBio Inc (ANAB) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
